Clinicopathological Evaluation of PD-L1 by Immunohistochemistry in Thyroid Carcinoma: A Prospective Tertiary Care Study
Journal of Current Oncological Trends · 2026-01 · 3 (1) · 10-15
DOI: 10.4103/jcot.jcot_4_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Oncological Trends, online erschienen am 31.07.2026. Verfasst von Sumit V. Kale und 7 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Context
Programmed death-ligand 1 (PD-L1) is an immune checkpoint molecule involved in tumor immune evasion and is a potential biomarker in thyroid carcinoma.
Aims
To evaluate PD-L1 expression and its association with clinicopathological parameters and Ki-67 index. Settings and Design: This hospital-based study was conducted in the Department of Pathology at Chittaranjan National Cancer Institute. A total of 63 histopathologically confirmed cases of thyroid carcinoma were enrolled during the study period from September 2022 to May 2024. Materials and Methods: Immunohistochemistry for PD-L1 and Ki-67 was performed. PD-L1 was assessed using Tumor Proportion Score, and Ki-67 was reported as percentage positivity. Statistical analysis included the chi-square and Pearson correlation tests.
Results
Females predominated (79.4%), with papillary thyroid carcinoma as the most common subtype (68.3%). PD-L1 expression was significantly higher in aggressive subtypes (anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma) ( P < 0.0001). Significant associations were observed with a higher Thyroid Imaging Reporting and Data System category ( P < 0.0001) and nodal metastasis ( P = 0.0160). PD-L1 showed a positive correlation with Ki-67 ( r = 0.827) and nodal status ( r = 0.796) and a negative correlation with age ( r = −0.655) and tumor size ( r = −0.371). The tumor stage showed no significant association.
Conclusion
PD-L1 expression correlates with aggressive features, metastasis, and proliferation in thyroid carcinoma, suggesting its role as a potential prognostic biomarker and therapeutic target.
Zitieren
APA
Kale, S. V., Choudhury, T., Pal, R., Roy, D., Chakrabarti, J., Dam, A., Hazra, S., & Nasare, V. D. (2026). Clinicopathological Evaluation of PD-L1 by Immunohistochemistry in Thyroid Carcinoma: A Prospective Tertiary Care Study. Journal of Current Oncological Trends, 3(1), 10-15. https://doi.org/10.4103/jcot.jcot_4_26
Vancouver
Kale SV, Choudhury T, Pal R, Roy D, Chakrabarti J, Dam A, et al. Clinicopathological Evaluation of PD-L1 by Immunohistochemistry in Thyroid Carcinoma: A Prospective Tertiary Care Study. Journal of Current Oncological Trends. 2026;3(1):10-15. doi:10.4103/jcot.jcot_4_26
BibTeX
@article{Kale2026,
author = {Kale, Sumit V. and Choudhury, Trisha and Pal, Ranita and Roy, Diya and Chakrabarti, Jayanta and Dam, Aniruddha and Hazra, Srabanti and Nasare, Vilas D.},
title = {Clinicopathological Evaluation of PD-L1 by Immunohistochemistry in Thyroid Carcinoma: A Prospective Tertiary Care Study},
journal = {Journal of Current Oncological Trends},
year = {2026},
volume = {3},
number = {1},
pages = {10--15},
doi = {10.4103/jcot.jcot_4_26}
}
EUVIMED